Mohammed H
Age 71 Β· Male
"βBefore, the pain was everywhere, and I thought this was the end. After the CAR-T treatment in China, I feel like a new person. The latest scan shows the cancer is almost gone. I am so grateful.β"
Diagnosed with aggressive multiple myeloma and widespread bone lesions, Mr. Mohamed achieved remarkable recovery after CAR-T therapy, showing dramatic PET/CT improvement, symptom resolution, restored strength, and a life he calls a second chance.
Mr Mohammed Multiple Myeloma Treatment with CAR T
Myeloma with extensive skeletal involvement is the first diagnosis. In July 2024, before starting treatment, PET/CT scans showed many active bone problems in both the spine and limbs. There were also numerous destructive lesions and a maximum SUV of 17.9, suggesting that the disease was actively progressing.
Mr. Mohamed sought more advanced treatment options as his condition deteriorated following standard chemotherapy, ultimately opting for targeted CAR-T cell immunotherapy in China.
The follow-up was conducted in September 2024, approximately two months after the therapy. What was found by repeated whole-body PET/CT scans:
The metabolic activity of all previously active lesions has significantly decreased. Several lesions healed entirely (no aberrant uptake of FDG). The highest SUV shrank from 17.9 to 5.16 cars. Consistent with response alterations after treatment, only moderate diffuse marrow uptake persisted.
Not a single new hypermetabolic foci in either soft tissues or bone. Shortly after the infusion, Mr. Mohamed became totally symptom-free. He calls the results, which include his strength returning, the absence of bone discomfort, and his ability to go about his everyday life as usual, "a second chance."
Why the Family Contacted CancerFax
After standard chemotherapy failed to adequately control Mr. Mohammed's myeloma, the family needed to identify centres in China with proven experience delivering CAR-T therapy for multiple myeloma β and to coordinate the pathway to access it safely and efficiently.
Mr. Mohammed's family needed to understand whether CAR-T β available in China β was appropriate for his specific myeloma profile and disease stage.
Not all CAR-T centres have equal experience with myeloma. Identifying the right institution required specialist knowledge of the CAR-T landscape in China.
Organising PET/CT reports, bone marrow biopsy results, chemotherapy history, and current disease status into a format that a Chinese clinical team could evaluate efficiently.
"Before, the pain was everywhere, and I thought this was the end. After the CAR-T treatment in China, I feel like a new person. The latest scan shows the cancer is almost gone. I am so grateful."β Mr. Mohammed, Patient
How CancerFax Helped
CancerFax reviewed Mr. Mohammed's case, identified a specialist CAR-T centre in China with relevant myeloma experience, and coordinated the evaluation and treatment access process β ensuring the clinical team had full context before his arrival.
PET/CT scans, bone marrow biopsy reports, chemotherapy history, and current disease markers were organised and prepared for specialist review.
A specialist CAR-T centre in China with documented experience in multiple myeloma treatment was identified based on Mr. Mohammed's disease profile.
Clinical documents were translated and the evaluation process coordinated with the Chinese clinical team to minimise delays.
Travel arrangements, accommodation, and hospital appointment scheduling were coordinated to reduce the logistical burden on the family.
Mohammed's Treatment Journey
From extensive bone disease and failed chemotherapy to PET/CT-confirmed response after CAR-T.
Mr. Mohammed was diagnosed with multiple myeloma affecting numerous bones across the spine and limbs. PET/CT in July 2024 showed a maximum SUV of 17.9 β indicating highly active, progressing disease.
Combination chemotherapy was initiated. Despite treatment, the disease continued to deteriorate, with worsening bone pain and declining physical condition.
As standard chemotherapy proved insufficient, Mr. Mohammed and his family decided to explore CAR-T cell immunotherapy β available at specialist centres in China.
CancerFax reviewed the case and identified an appropriate CAR-T centre in China. Medical records were compiled and the evaluation process coordinated.
Mr. Mohammed received targeted CAR-T cell immunotherapy at the identified centre. The treatment proceeded and he was monitored closely throughout.
Follow-up PET/CT in September 2024 β approximately two months post-treatment β showed: metabolic activity significantly reduced across all previously active lesions; several lesions healed completely; maximum SUV dropped from 17.9 to 5.16; no new lesions detected. Mr. Mohammed became fully symptom-free shortly after infusion.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Mohammed Is Today
Two months after CAR-T cell therapy, Mr. Mohammed's follow-up PET/CT told a dramatically different story from his pre-treatment scans. The metabolic activity of all previously active lesions had significantly decreased. Several had healed entirely, with no abnormal FDG uptake. The maximum SUV had fallen from 17.9 to 5.16. No new lesions had appeared anywhere in the body.
Shortly after the infusion, Mr. Mohammed became completely symptom-free. The bone pain that had been constant and debilitating was gone. His strength returned. He resumed daily activities.
He describes his outcome as "a second chance" β and the improvement in his quality of life as something he did not believe was still possible when he arrived in China.
β"Before, the pain was everywhere, and I thought this was the end. After the CAR-T treatment in China, I feel like a new person. The latest scan shows the cancer is almost gone. I am so grateful."ββ Mr. Mohammed, Patient
What Other Families Can Learn
Mr. Mohammed's story reflects a situation that many myeloma patients and families encounter β and offers practical lessons about when and how to explore advanced treatment options.
When myeloma does not respond adequately to standard chemotherapy, CAR-T β which works through a fundamentally different immune-based mechanism β may produce a response where cytotoxic approaches have not.
CAR-T for myeloma requires specific institutional expertise. Identifying centres with documented outcomes in myeloma β not just in lymphoma or leukemia β matters for patient safety and effectiveness.
Waiting for multiple chemotherapy lines to fail before seeking specialist CAR-T evaluation can reduce eligibility and narrow options. Earlier exploration of international pathways preserves more choices.
SUV values and metabolic response on PET/CT provide objective, quantifiable evidence of treatment effect in myeloma β particularly in assessing skeletal disease burden before and after therapy.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.